Qualidade de vida: os benefícios que a toxina botulínica pode agregar na vida de pacientes com doença de Parkinson
Carregando...
Data
2022-12-05
Tipo de documento
Artigo Científico
Título da Revista
ISSN da Revista
Título de Volume
Área do conhecimento
Ciências da Saúde
Modalidade de acesso
Acesso fechado
Editora
Autores
Müller, Ágata Rosa
Orientador
Grah, Matheus
Coorientador
Resumo
A toxina botulínica (TXB) é uma proteína produzida pela bactéria do gênero Clostridium botulinum, descoberta no ano de 1895, consiste em uma neurotoxina que paralisa a musculatura, bloqueando a liberação de acetilcolina, fazendo com que a musculatura perca sua força de contração. A TXB é amplamente utilizada para fins estéticos, contudo, em 1989, o médico alemão Justinus Kerner propôs o uso da toxina para fins terapêuticos. O uso da TXB para distonias é uma das indicações mais importantes, utilizada para sintomas decorrentes da Doença de Parkinson (DP). A DP é um distúrbio neurodegenerativo progressivo do movimento. Diversos efeitos motores e não motores acometem pacientes com Parkinson, tais como os sintomas de alterações motoras, sensitivos, psiquiátricos e cardíacos, como: bradicinesia, rigidez, instabilidade postural e tremor. Os pacientes que utilizaram TXB experimentaram alívio dos sintomas sem efeitos indesejáveis, já que os fármacos orais anticolinérgicos, utilizados nesses pacientes, possuem um alto grau de efeito adverso. Tendo em vista o grande potencial de aplicabilidade terapêutica da TXB, pode-se considerar o uso seguro e eficiente para o controle de alguns sintomas de Parkinson, visto que possuem comprovações de melhora na qualidade de vida dos pacientes acometidos. O objetivo deste projeto é apresentar uma revisão narrativa da literatura sobre as aplicações terapêuticas da toxina botulínica a fim de minimizar sintomas desenvolvidos na patologia de Parkinson
Botulinum toxin (TXB) is a protein produced by bacteria of the genus Clostridium botulinum, discovered in 1895, consisting of a neurotoxin that paralyzes the muscles, blocking the release of acetylcholine, causing the muscles to lose their contraction strength. TXB is widely used for aesthetic purposes, however, in 1989, the German physician Justinus Kerner proposed the use of the toxin for therapeutic purposes. The use of TXB for dystonias is one of the most important indications, used for symptoms resulting from Parkinson's Disease (PD). PD is a progressive neurodegenerative movement disorder. Several motor and non-motor effects affect patients with Parkinson's, such as symptoms of motor, sensory, psychiatric and cardiac changes, such as: bradykinesia, rigidity, postural instability and tremor. Patients who used TXB experienced relief of symptoms without undesirable effects, since the oral anticholinergic drugs used in these patients have a high degree of adverse effects. Bearing in mind the great potential for therapeutic applicability of TXB, its safe and efficient use can be considered to control some Parkinson's symptoms, since it has evidence of improvement in the quality of life of affected patients. The objective of this project is to present a narrative review of the literature on the therapeutic applications of botulinum toxin in order to minimize symptoms developed in Parkinson's pathology
Botulinum toxin (TXB) is a protein produced by bacteria of the genus Clostridium botulinum, discovered in 1895, consisting of a neurotoxin that paralyzes the muscles, blocking the release of acetylcholine, causing the muscles to lose their contraction strength. TXB is widely used for aesthetic purposes, however, in 1989, the German physician Justinus Kerner proposed the use of the toxin for therapeutic purposes. The use of TXB for dystonias is one of the most important indications, used for symptoms resulting from Parkinson's Disease (PD). PD is a progressive neurodegenerative movement disorder. Several motor and non-motor effects affect patients with Parkinson's, such as symptoms of motor, sensory, psychiatric and cardiac changes, such as: bradykinesia, rigidity, postural instability and tremor. Patients who used TXB experienced relief of symptoms without undesirable effects, since the oral anticholinergic drugs used in these patients have a high degree of adverse effects. Bearing in mind the great potential for therapeutic applicability of TXB, its safe and efficient use can be considered to control some Parkinson's symptoms, since it has evidence of improvement in the quality of life of affected patients. The objective of this project is to present a narrative review of the literature on the therapeutic applications of botulinum toxin in order to minimize symptoms developed in Parkinson's pathology
Palavras-chave
Doença de Parkinson, Distonias, Déficit motor, Toxina botulínica